Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1708115
PUBLISHER: BCC Research | PRODUCT CODE: 1708115
Cancer Immunotherapy: Technologies and Global Markets
PUBLISHED:
PAGES: 203 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
The cancer immunotherapy market for checkpoint inhibitors is expected to grow from $64.0 billion in 2024 and is projected to reach $107.8 billion by the end of 2029, at a CAGR of 11.0% during the forecast period of 2024 to 2029.
The cancer immunotherapy market for monoclonal antibodies is expected to grow from $44.5 billion in 2024 and is projected to reach $80.4 billion by the end of 2029, at a CAGR of 12.5% during the forecast period of 2024 to 2029.
Report Scope
This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy's current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024-2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.
In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.
The report aims to:
- Analyze therapies and types of cancer.
- Analyze global market size and segmentation.
- Understand market constraints and drivers.
- Provide detailed market forecasts for 2029.
- Assess market shares, competitiveness and industry structure.
- Identify potential long-term impacts on the cancer immunotherapy market.
Report Includes
- 75 data tables and 54 additional tables
- An analysis of the global cancer immunotherapy market
- Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region
- Coverage of treatments that are in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
- Evaluation of recent patent activity and key granted and published patents in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca
Product Code: PHM129C
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Porter's Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential for New Entrants
- Threat of Substitutes
- Competitiveness in the Industry
- Key Concepts of Immunotherapy
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Rising Cancer Cases Globally
- Robust Approval of Immunotherapy Drugs
- Rise in Government Funding and Pharmaceutical R&D Spending
- Market Restraints
- High Cost of Immunotherapy
- Loss of Exclusivity and Genericization
- Shortage of Oncology Professionals
- Market Opportunities
- Technological Advances in Immunotherapy
- Potential in Cancer Immunotherapy
Chapter 4 Regulatory Landscape
- Overview
- U.S.
- Europe
- Japan
Chapter 5 Emerging Technologies
- Overview
- Artificial Intelligence (AI)
- Emergent Biomarkers
- Immunotherapy Pipeline
- Patent Analysis
- Future Prospects
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Global Market for Cancer Immunotherapy, by Therapy Type
- Global Market Size and Forecast
- Checkpoint Inhibitors
- Monoclonal Antibodies
- Adoptive Cell Therapies
- Cytokine Therapy
- Cancer Vaccines
- Oncolytic Virus Therapy
- Other Immunotherapies
- Global Market for Cancer Immunology, by Cancer Type
- Global Market Size and Forecast
- Melanoma
- Leukemia
- Lymphoma
- Myeloma
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Other Cancers
- Geographic Breakdown
- Global Market for Cancer Immunotherapy, by Region
- Global Market Size and Forecast
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Overview
- Competitive Landscape
- Company Share Analysis
Chapter 8 Sustainability in Cancer Immunotherapy Market: An ESG Perspective
- Introduction to ESG
- Role of ESG in the Pharma Industry
- Sustainability in the Cancer Immunotherapy Market
- ESG Perspective
- Environmental Impact
- Social Impact
- Governance Impact
- ESG Risk Ratings
- Conclusion
Chapter 9 Appendix
- Methodology
- Abbreviations
- Sources
- Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
Product Code: PHM129C
List of Tables
- Summary Table : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 1 : Porter's Five Forces Analysis: Cancer Immunotherapy Market
- Table 2 : Average Price of Immunotherapy
- Table 3 : List of Selected Clinical Trial Studies on Immunotherapy, 2025
- Table 4 : List of Selected Recent Patents Related to Immunotherapy 2024-2025
- Table 5 : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 6 : FDA-Approved Immune Checkpoint Inhibitors 2015-2018
- Table 7 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Region, Through 2029
- Table 8 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Type, Through 2029
- Table 9 : Global Market for Monoclonal Antibodies in Cancer Immunotherapy, by Region, Through 2029
- Table 10 : Global Market for Adoptive Cell Therapies in Cancer Immunotherapy, by Region, Through 2029
- Table 11 : Global Market for Cytokine Therapy in Cancer Immunotherapy, by Region, Through 2029
- Table 12 : Global Market for Cancer Vaccines in Cancer Immunotherapy, by Region, Through 2029
- Table 13 : Players Investing in Oncolytic Virology, 2024
- Table 14 : Global Market for Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, Through 2029
- Table 15 : Global Market for Other Immunotherapies in Cancer Immunotherapy, by Region, Through 2029
- Table 16 : Global Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 17 : Global Market for Cancer Immunotherapy in Melanoma, by Region, Through 2029
- Table 18 : Global Market for Cancer Immunotherapy in Leukemia, by Region, Through 2029
- Table 19 : Global Market for Cancer Immunotherapy in Lymphoma, by Region, Through 2029
- Table 20 : Global Market for Cancer Immunotherapy in Myeloma, by Region, Through 2029
- Table 21 : Global Market for Cancer Immunotherapy in Lung Cancer, by Region, Through 2029
- Table 22 : Global Market for Cancer Immunotherapy in Breast Cancer, by Region, Through 2029
- Table 23 : Global Market for Cancer Immunotherapy in Colorectal Cancer, by Region, Through 2029
- Table 24 : Global Market for Cancer Immunotherapy in Other Cancers, by Region, Through 2029
- Table 25 : Global Market for Cancer Immunotherapy, by Region, Through 2029
- Table 26 : North American Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 27 : North American Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 28 : North American Market for Cancer Immunotherapy, by Country, Through 2029
- Table 29 : U.S. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 30 : U.S. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 31 : Canadian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 32 : Canadian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 33 : Mexican Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 34 : Mexican Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 35 : European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 36 : European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 37 : European Market for Cancer Immunotherapy, by Country, Through 2029
- Table 38 : German Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 39 : German Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 40 : U.K. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 41 : U.K. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 42 : French Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 43 : French Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 44 : Italian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 45 : Italian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 46 : Spanish Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 47 : Spanish Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 48 : Rest of European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 49 : Rest of European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 50 : Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 51 : Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 52 : Asia-Pacific Market for Cancer Immunotherapy, by Country, Through 2029
- Table 53 : Chinese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 54 : Chinese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 55 : Japanese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 56 : Japanese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 57 : Indian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 58 : Indian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 59 : Australian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 60 : Australian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 61 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 62 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 63 : Rest of the World Market for Cancer Immunotherapy, by Therapy Type, Through 2029
- Table 64 : Rest of the World Market for Cancer Immunotherapy, by Cancer Type, Through 2029
- Table 65 : Key Focus Areas in ESG Metrics
- Table 66 : ESG Rankings for Leading Companies in Cancer Immunotherapy Market, 2024*
- Table 67 : Abbreviations Used in this Report.
- Table 68 : Report Sources
- Table 69 : AbbVie Inc.: Company Snapshot
- Table 70 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
- Table 71 : AbbVie Inc.: Product Portfolio
- Table 72 : AbbVie Inc.: News/Key Developments, 2023 and 2024
- Table 73 : Amgen Inc.: Company Snapshot
- Table 74 : Amgen Inc.: Financial Performance, FY 2022 and 2023
- Table 75 : Amgen Inc.: Product Portfolio
- Table 76 : Amgen Inc.: News/Key Developments, 2022-2024
- Table 77 : AstraZeneca: Company Snapshot
- Table 78 : AstraZeneca: Financial Performance, FY 2022 and 2023
- Table 79 : AstraZeneca: Product Portfolio
- Table 80 : AstraZeneca: News/Recent Developments, 2023 and 2024
- Table 81 : Bristol-Myers Squibb Co.: Company Snapshot
- Table 82 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
- Table 83 : Bristol-Myers Squibb Co.: Product Portfolio
- Table 84 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
- Table 85 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 86 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
- Table 87 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 88 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
- Table 89 : Gilead Sciences Inc.: Company Snapshot
- Table 90 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
- Table 91 : Gilead Sciences Inc.: Product Portfolio
- Table 92 : Gilead Sciences Inc.: News/Key Developments, 2023 and 2024
- Table 93 : Johnson & Johnson Services Inc.: Company Snapshot
- Table 94 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
- Table 95 : Johnson & Johnson Services Inc.: Product Portfolio
- Table 96 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
- Table 97 : Lilly: Company Snapshot
- Table 98 : Lilly: Financial Performance, FY 2022 and 2023
- Table 99 : Lilly: Product Portfolio
- Table 100 : Lilly: News/Key Developments, 2022 and 2023
- Table 101 : Merck & Co. Inc.: Company Snapshot
- Table 102 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
- Table 103 : Merck & Co. Inc.: Product Portfolio
- Table 104 : Merck & Co. Inc.: News/Key Developments, 2021-2024
- Table 105 : Novartis AG: Company Snapshot
- Table 106 : Novartis AG: Financial Performance, FY 2022 and 2023
- Table 107 : Novartis AG: Product Portfolio
- Table 108 : Novartis AG: News/Key Developments, 2022
- Table 109 : Pfizer Inc.: Company Snapshot
- Table 110 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
- Table 111 : Pfizer Inc.: Product Portfolio
- Table 112 : Pfizer Inc.: News/Key Developments, 2023 and 2024
- Table 113 : Regeneron Pharmaceuticals Inc.: Company Snapshot
- Table 114 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
- Table 115 : Regeneron Pharmaceuticals Inc.: Product Portfolio
- Table 116 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
- Table 117 : Sanofi: Company Snapshot
- Table 118 : Sanofi: Financial Performance, FY 2022 and 2023
- Table 119 : Sanofi: Product Portfolio
- Table 120 : Sanofi: News/Key Developments, 2022-2024
- Table 121 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
- Table 122 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
- Table 123 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
- Table 124 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
- Table 125 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
- Table 126 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
- Table 127 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
- Table 128 : Few Emerging Players in Cancer Immunotherapy Market
List of Figures
- Summary Figure : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 1 : Snapshot of Market Dynamics
- Figure 2 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
- Figure 3 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
- Figure 4 : Estimated New Cancer Cases and Deaths in the U.S. in 2024
- Figure 5 : National Cancer Institute Research Funding, 2012-2019
- Figure 6 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
- Figure 7 : Immunotherapy-Related Patents and Publications in the U.S. and China
- Figure 8 : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 9 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Region, 2023
- Figure 10 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Type, 2023
- Figure 11 : Global Market Shares of Monoclonal Antibodies in Cancer Immunotherapy, by Region, 2023
- Figure 12 : Global Market Shares of Adoptive Cell Therapies in Cancer Immunotherapy, by Region, 2023
- Figure 13 : Global Market Shares of Cytokine Therapy in Cancer Immunotherapy, by Region, 2023
- Figure 14 : Global Market Shares of Cancer Vaccines in Cancer Immunotherapy, by Region, 2023
- Figure 15 : Global Market Shares of Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, 2023
- Figure 16 : Global Market Shares of Other Immunotherapies in Cancer Immunotherapy, by Region, 2023
- Figure 17 : Global Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 18 : Global Market Shares of Cancer Immunotherapy in Melanoma, by Region, 2023
- Figure 19 : Global Market Shares of Cancer Immunotherapy in Leukemia, by Region, 2023
- Figure 20 : Global Market Shares of Cancer Immunotherapy in Lymphoma, by Region, 2023
- Figure 21 : Global Market Shares of Cancer Immunotherapy in Myeloma, by Region, 2023
- Figure 22 : Global Market Shares of Cancer Immunotherapy in Lung Cancer, by Region, 2023
- Figure 23 : Global Market Shares of Cancer Immunotherapy in Breast Cancer, by Region, 2023
- Figure 24 : Global Market Shares of Cancer Immunotherapy in Colorectal Cancer, by Region, 2023
- Figure 25 : Global Market Shares of Cancer Immunotherapy in Other Cancers, by Region, 2023
- Figure 26 : Global Market Shares of Cancer Immunotherapy, by Region, 2023
- Figure 27 : North American Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 28 : North American Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 29 : North American Market Shares of Cancer Immunotherapy, by Country, 2023
- Figure 30 : U.S. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 31 : U.S. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 32 : Canadian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 33 : Canadian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 34 : Mexican Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 35 : Mexican Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 36 : European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 37 : European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 38 : European Market Shares of Cancer Immunotherapy, by Country, 2023
- Figure 39 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 40 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 41 : U.K. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 42 : U.K. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 43 : French Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 44 : French Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 45 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 46 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 47 : Spanish Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 48 : Spanish Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 49 : Rest of European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 50 : Rest of European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 51 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 52 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 53 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Country, 2023
- Figure 54 : Chinese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 55 : Chinese Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 56 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 57 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 58 : Indian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 59 : Indian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 60 : Australian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 61 : Australian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 62 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 63 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 64 : Rest of the World Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
- Figure 65 : Rest of the World Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
- Figure 66 : Top 10 Blockbuster Cancer Immunotherapy Products, by Sales Revenue, 2022-2023
- Figure 67 : Global Market Shares of Cancer Immunotherapy, by Company, 2023
- Figure 68 : Pillars of ESG
- Figure 69 : Advantages of ESG for Companies
- Figure 70 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 71 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 72 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 73 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 74 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
- Figure 75 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
- Figure 76 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
- Figure 77 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
- Figure 78 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
- Figure 79 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
- Figure 80 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 81 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 82 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 83 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 84 : Lilly: Revenue Share, by Business Unit, FY 2023
- Figure 85 : Lilly: Revenue Share, by Country/Region, FY 2023
- Figure 86 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 87 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 88 : Novartis AG: Revenue Share, by Business Unit, FY 2023
- Figure 89 : Novartis AG: Revenue Share, by Country/Region, FY 2023
- Figure 90 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 91 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 92 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 93 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 94 : Sanofi: Revenue Share, by Business Unit, FY 2023
- Figure 95 : Sanofi: Revenue Share, by Country/Region, FY 2023
- Figure 96 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
- Figure 97 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
- Figure 98 : Teva Pharmaceutical Industries Ltd.: Market Share, by Business Unit, FY 2023
- Figure 99 : Teva Pharmaceutical Industries Ltd.: Market Share, by Country/Region, FY 2023
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.